Items tagged with Treatment
Substituting bedaquiline for second-line injectables improves MDR-TB treatment (post)
Findings from a recent study support substituting bedaquiline for second-line injectables in treatment for multidrug-resistant tuberculosis, with researchers reporting improved outcomes at 12 months compared with patients who remained on second-line injectables.
Documentary: Two Countries, Two Choices: India, South Africa and the struggle against MDR-TB (post)
A new documentary film by AIDS-Free World: The drugs bedaquiline and delamanid can mean the difference between life and death for people suffering from the worst and most noxious strain of TB in the world, multidrug-resistant TB (MDR-TB). The government of India has restricted access to the drugs for its 140,000 MDR-TB sufferers. South Africa has made a different choice for 20,000 MDR-TB patients. The consequences are profound.
Delamanid delay comes home (post)
A note from the field in this week’s Morbidity and Mortality Weekly Report describes the case of a dangerously ill man in the United States. Weak, coughing, and losing weight, with pain in his chest, he was tested for tuberculosis, which it turned out he had, and put on the first-line of treatment for the disease.
Complete makeover in fight of multidrug-resistant TB (post)
Montreal, Sep 6, 2018 – Several new medicines have been found to be more effective than traditional ones used to treat multidrug-resistant tuberculosis (MDR-TB), according to a new international collaborative study led by Dr. Dick Menzies, senior scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal. These findings precipitated a complete overhaul of worldwide TB treatment guidelines, with the results of this work published today in the British medical journal The Lancet.
Better and safer treatment for multidrug-resistant TB (post)
Paul Farmer in a comment, published in The Lancet, reflects on the "new era" of better and safer treatment for multidrug-resistant TB.
TB Alliance and Liverpool School of Tropical Medicine collaborate to develop new TB therapies (post)
LIVERPOOL (September 19, 2018) – The Liverpool School of Tropical Medicine (LSTM) and TB Alliance are collaborating to investigate novel combination drug therapies that could help the fight against multidrug-resistant tuberculosis (MDR-TB), following an award of £1 million from the Medical Research Council.
Johnson & Johnson announces 10-year initiative to help end TB, the world’s #1 infectious killer (post)
J&J’s goal is to save an estimated 1.8 million lives and prevent 12 million new TB infections.
Unitaid extends key research grant as part of a strong counterattack on TB (post)
New York, 25 September 2018 – Unitaid is intensifying its commitment to fighting tuberculosis with a US$ 21 million investment in extending endTB, a global research project that is improving treatment regimens for patients with multidrug-resistant tuberculosis (MDR-TB).
UK pledges funding to speed up TB treatment (post)
The UK government has pledged £7.5million for the development of three new treatments for tuberculosis, the world's biggest infectious disease killer.
Activists: Call on your countries to use bedaquiline-based regimens to treat TB (post)
The Global Coalition of TB Activists (GCTA), Treatment Action Group (TAG) and the DR-TB Scale-Up Treatment Action Team (DR-TB STAT) developed a letter template to help activists call for bedaquiline-based, injectable-free regimens for the treatment of drug-resistant TB in their countries.
Page 42 of 108 · Total posts: 0
←First 41 42 43 Last→